Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

53 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Efficacy and Safety of Bimagrumab in Sporadic Inclusion Body Myositis: Long-term Extension of RESILIENT.
Amato AA, Hanna MG, Machado PM, Badrising UA, Chinoy H, Benveniste O, Karanam AK, Wu M, Tankó LB, Schubert-Tennigkeit AA, Papanicolaou DA, Lloyd TE, Needham M, Liang C, Reardon KA, de Visser M, Ascherman DP, Barohn RJ, Dimachkie MM, Miller JAL, Kissel JT, Oskarsson B, Joyce NC, Van den Bergh P, Baets J, De Bleecker JL, Karam C, David WS, Mirabella M, Nations SP, Jung HH, Pegoraro E, Maggi L, Rodolico C, Filosto M, Shaibani AI, Sivakumar K, Goyal NA, Mori-Yoshimura M, Yamashita S, Suzuki N, Aoki M, Katsuno M, Morihata H, Murata K, Nodera H, Nishino I, Romano CD, Williams VSL, Vissing J, Zhang Auberson L; RESILIENT Study Extension Group. Amato AA, et al. Among authors: badrising ua. Neurology. 2021 Mar 23;96(12):e1595-e1607. doi: 10.1212/WNL.0000000000011626. Epub 2021 Feb 17. Neurology. 2021. PMID: 33597289 Free PMC article. Clinical Trial.
['Inclusion body'-myositis].
Badrising UA, Maat-Schieman ML, van Duinen SG, van Dijk JG, Verschuuren JJ, Wintzen AR. Badrising UA, et al. Ned Tijdschr Geneeskd. 1998 Mar 14;142(11):553-7. Ned Tijdschr Geneeskd. 1998. PMID: 9623110 Dutch.
Epidemiology of inclusion body myositis in the Netherlands: a nationwide study.
Badrising UA, Maat-Schieman M, van Duinen SG, Breedveld F, van Doorn P, van Engelen B, van den Hoogen F, Hoogendijk J, Höweler C, de Jager A, Jennekens F, Koehler P, van der Leeuw H, de Visser M, Verschuuren JJ, Wintzen AR. Badrising UA, et al. Neurology. 2000 Nov 14;55(9):1385-7. doi: 10.1212/wnl.55.9.1385. Neurology. 2000. PMID: 11087787
Comparison of weakness progression in inclusion body myositis during treatment with methotrexate or placebo.
Badrising UA, Maat-Schieman ML, Ferrari MD, Zwinderman AH, Wessels JA, Breedveld FC, van Doorn PA, van Engelen BG, Hoogendijk JE, Höweler CJ, de Jager AE, Jennekens FG, Koehler PJ, de Visser M, Viddeleer A, Verschuuren JJ, Wintzen AR. Badrising UA, et al. Ann Neurol. 2002 Mar;51(3):369-72. doi: 10.1002/ana.10121. Ann Neurol. 2002. PMID: 11891832 Clinical Trial.
Associations with autoimmune disorders and HLA class I and II antigens in inclusion body myositis.
Badrising UA, Schreuder GM, Giphart MJ, Geleijns K, Verschuuren JJ, Wintzen AR, Maat-Schieman ML, van Doorn P, van Engelen BG, Faber CG, Hoogendijk JE, de Jager AE, Koehler PJ, de Visser M, van Duinen SG; Dutch IBM Study Group. Badrising UA, et al. Neurology. 2004 Dec 28;63(12):2396-8. doi: 10.1212/01.wnl.0000148588.15052.4c. Neurology. 2004. PMID: 15623710
Detecting dysphagia in inclusion body myositis.
Cox FM, Verschuuren JJ, Verbist BM, Niks EH, Wintzen AR, Badrising UA. Cox FM, et al. Among authors: badrising ua. J Neurol. 2009 Dec;256(12):2009-13. doi: 10.1007/s00415-009-5229-9. Epub 2009 Jul 15. J Neurol. 2009. PMID: 19603245 Free PMC article.
The heart in sporadic inclusion body myositis: a study in 51 patients.
Cox FM, Delgado V, Verschuuren JJ, Ballieux BE, Bax JJ, Wintzen AR, Badrising UA. Cox FM, et al. Among authors: badrising ua. J Neurol. 2010 Mar;257(3):447-51. doi: 10.1007/s00415-009-5350-9. Epub 2009 Oct 8. J Neurol. 2010. PMID: 19813068 Free PMC article.
53 results